• Cyclopharm secures 5-year Federal Supply Schedule agreement with US Veterans Administration
• Streamlines procurement and ensures consistent supply of Technegas patient consumables
• Strengthens partnership and expands Technegas adoption within US federal healthcare system

Cyclopharm Limited (ASX: CYC) has announced that its Interim Agreement (IA) with the Veterans Health Administration (VA), announced on 3 October 2024, has successfully transitioned to a five-year Federal Supply Schedule (FSS) agreement. The FSS agreement represents a significant milestone in expanding Technegas' adoption within the US federal healthcare system. It simplifies procurement processes for US federal agencies, including the 120 Veterans Administration (VA) hospitals, the Department of Defense (DoD), and Public Health Service (PHS) hospitals. By eliminating the need for individual contracts across the VA's 20 Regional Procurement Offices, this agreement enhances efficiency and ensures consistent supply of Technegas patient consumables. Cyclopharm CEO James McBrayer stated that securing this five-year Federal Supply Schedule agreement is a major achievement for Cyclopharm's expansion in the US market. The contract strengthens the company's partnership with the VA, underscores the clinical value of Technegas for US veterans, and streamlines access to the technology across federal healthcare facilities. Cyclopharm remains confident in the medium to long-term growth of Technegas within the VA system and other federal healthcare facilities.

As stated last month in the Company's full year results announcement, uncertainty around the evolving policy landscape in the US relating to healthcare funding may influence the timing of contract completion in the near term.